mp.weixin.qq.com·· 4 hours agoPickScore84
Professor Chen Liming Explains GZR4 SUPER-1 Phase 3 Superior HbA1c Results at EASD 2026
In brief
Results of the SUPER-1 phase 3 trial, presented by Professor Chen Liming at EASD 2026, show that once-weekly GZR4 achieved a greater 26-week HbA1c reduction than once-daily insulin glargine U100. The multicenter, randomized, open-label phase 3a study enrolled 589 insulin-naive patients with type 2 diabetes; HbA1c fell 1.45% versus 1.22% from baseline, with an ETD of -0.23% (95% CI -0.34 to -0.12, P < 0.0001).
Why it matters
SUPER-1 compared weekly GZR4 with once-daily insulin glargine U100 in 589 patients on 26-week glycemic control, target attainment, and hypoglycemia outcomes, helping define the benefit and safety of starting with a weekly insulin.
Source: mp.weixin.qq.com · mp.weixin.qq.com